Cara Therapeutics Inc (NASDAQ: CARA) stock closed at $6.69 on 10/13/25 after a major decline of -83.9%. Moreover, trading volume in this decline was exceptionally high at 3690% of normal. The stock has declined -83.4% during the last week but has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
Cara Therapeutics is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment